These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 2677758)

  • 1. [Immunotherapy of cancer with interleukin-2 and with interleukin-2 activated cells].
    Osanto S; Brand A; van Rood JJ; Cleton FJ
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1392-5. PubMed ID: 2677758
    [No Abstract]   [Full Text] [Related]  

  • 2. [Adoptive immunotherapy with interleukin-2 and with interleukin-2 activated lymphocytes].
    Eggermont AM; Stoter G; Jansen RL; Bolhuis RL
    Ned Tijdschr Geneeskd; 1989 Jul; 133(28):1387-92. PubMed ID: 2677757
    [No Abstract]   [Full Text] [Related]  

  • 3. LAK cell therapy--clinical studies and future potential.
    Marshall GD; Schwartzberg LS; Tauer KW; Lee P; Holbert JM; West WH
    Prog Clin Biol Res; 1990; 337():555-8. PubMed ID: 2191342
    [No Abstract]   [Full Text] [Related]  

  • 4. [Adoptive immunotherapy using interleukin-2 and interleukin-2-activated lymphocytes].
    van de Loosdrecht AA; Ossenkoppele GJ; Beelen RH
    Ned Tijdschr Geneeskd; 1989 Oct; 133(40):1994-5. PubMed ID: 2812087
    [No Abstract]   [Full Text] [Related]  

  • 5. Clinical use of interleukin-2 in treating cancer.
    Patterson DL; Wiemann MC
    Indiana Med; 1991 Aug; 84(8):534-7. PubMed ID: 1918915
    [No Abstract]   [Full Text] [Related]  

  • 6. Severe hypovitaminosis C occurring as the result of adoptive immunotherapy with high-dose interleukin 2 and lymphokine-activated killer cells.
    Marcus SL; Dutcher JP; Paietta E; Ciobanu N; Strauman J; Wiernik PH; Hutner SH; Frank O; Baker H
    Cancer Res; 1987 Aug; 47(15):4208-12. PubMed ID: 3496958
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adoptive immunotherapy of cancer using lymphokine activated killer cells and recombinant interleukin-2.
    Rosenberg SA
    Important Adv Oncol; 1986; ():55-91. PubMed ID: 3330541
    [No Abstract]   [Full Text] [Related]  

  • 8. [Treatment of malignant tumors by interleukin 2 and LAK cells].
    Degos L
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):119-22. PubMed ID: 3260373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. "Lymphokine activated killing" as treatment for human cancer: clinical extrapolations from laboratory studies with interleukin-2 expanded leukocytes.
    Sondel PM; Hank JA; Kohler PC; Chen BP; Sosman J
    Prog Clin Biol Res; 1989; 288():151-60. PubMed ID: 2654949
    [No Abstract]   [Full Text] [Related]  

  • 10. Extracorporeal immunomodulation in patients with hepatocellular carcinoma with lymphokine activated killer cells.
    Saibara T; Fujikawa M; Iwamura S; Matsuura Y; Ido E; Sakaeda H; Tomita A; Matsunaga Y; Maeda T; Onishi S
    Prog Clin Biol Res; 1990; 337():459-67. PubMed ID: 2162063
    [No Abstract]   [Full Text] [Related]  

  • 11. Lymphokine-activated killer lymphocytes: National Cancer Institute clinical trials.
    Clark J; Longo DL
    Immunol Ser; 1989; 48():37-58. PubMed ID: 2488325
    [No Abstract]   [Full Text] [Related]  

  • 12. Treatment with pentoxifylline and ciprofloxacin reduces the toxicity of high-dose interleukin-2 and lymphokine-activated killer cells.
    Thompson JA; Benyunes MC; Bianco JA; Fefer A
    Semin Oncol; 1993 Dec; 20(6 Suppl 9):46-51. PubMed ID: 8284692
    [No Abstract]   [Full Text] [Related]  

  • 13. Lymphokine-activated killer lymphocytes: biotherapeutics clinical trials.
    West WH
    Immunol Ser; 1989; 48():79-92. PubMed ID: 2488327
    [No Abstract]   [Full Text] [Related]  

  • 14. Lymphokine-activated killer lymphocytes: extramural clinical trials.
    Sniecinski IJ
    Immunol Ser; 1989; 48():59-77. PubMed ID: 2488326
    [No Abstract]   [Full Text] [Related]  

  • 15. Interleukin-2 and lymphokine-activated killer cell therapy for gastrointestinal cancer.
    Guillou P
    Acta Chir Scand Suppl; 1989; 549():26-30. PubMed ID: 2784604
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical trials with IL-2.
    Seipp CA; Simpson C; Rosenberg SA
    Oncol Nurs Forum; 1986; 13(6):25-9. PubMed ID: 3540866
    [No Abstract]   [Full Text] [Related]  

  • 17. Lymphokine-activated killer cells: a new approach to immunotherapy of cancer.
    Rosenberg S
    J Natl Cancer Inst; 1985 Oct; 75(4):595-603. PubMed ID: 3876465
    [No Abstract]   [Full Text] [Related]  

  • 18. Cellular immunotherapy of cancer.
    Topalian SL; Rosenberg SA
    Crit Care Med; 1990 Feb; 18(2 Suppl):S144. PubMed ID: 2298029
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of residual disease in acute leukemia patients with recombinant interleukin 2 (IL2): clinical and biological findings.
    Foa R; Meloni G; Tosti S; Novarino A; Fenu S; Guarini A; Cardona S; Gillio Tos A; Gavosto F; Mandelli F
    Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():98-102. PubMed ID: 2202476
    [No Abstract]   [Full Text] [Related]  

  • 20. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
    Rosenberg SA
    J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.